Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:28:47.754Z.
Calculation as of: 2026-10-06T21:28:47.754Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4fd5d7af3ee6af72921bc315e5ba82b5757c441ca2a41ed9c1ba6c6f3afb8810
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Regencell Bioscience Holdings Limited
Market Cap
$3.64B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.56B
EV/EBITDA Ratio
28.34x
TTM Avg
48.38x
3Y Avg
232403.53x
5Y Avg
232403.53x
Market Cap
$3.54B
EV/EBITDA Ratio
N/A
TTM Avg
11.43x
3Y Avg
11.37x
5Y Avg
11.37x
Market Cap
$3.52B
EV/EBITDA Ratio
286.35x
TTM Avg
665.65x
3Y Avg
665.65x
5Y Avg
665.65x
Market Cap
$3.38B
EV/EBITDA Ratio
31.19x
TTM Avg
29.77x
3Y Avg
69.20x
5Y Avg
69.20x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Regencell Bioscience Holdings Limited (RGC) | $3.64B | N/A | N/A | N/A | N/A |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | N/A | N/A | N/A | N/A |
| Veracyte, Inc. (VCYT)vs › | $3.56B | 28.34x | 48.38x | 232403.53x | 232403.53x |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | N/A | 11.43x | 11.37x | 11.37x |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | 286.35x | 665.65x | 665.65x | 665.65x |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | N/A | N/A | N/A | N/A |
| Celcuity Inc. (CELC)vs › | $3.47B | N/A | N/A | N/A | N/A |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 31.19x | 29.77x | 69.20x | 69.20x |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
